Biophytis (EPA:ALBPS)

BRIEF

published on 01/28/2026 at 07:35, 2 days 8 hours ago

Biophytis Secures $20 Million for Sarcopenia Phase 3 Trial in Asia

Biophytis Joint Venture Phase 3 Trial Sarcopenia Asian Markets
REGULATED PRESS RELEASE

published on 01/28/2026 at 07:30, 2 days 8 hours ago

Biophytis enters strategic agreement in Asia and secures $20 million for launch of Phase 3 trial in sarcopenia
Biophytis announces strategic agreement in Asia and secures $20 million for Phase 3 trial in sarcopenia, including creation of joint venture in Hong Kong and financing over 3 years

Biophytis Joint Venture Phase 3 Trial Sarcopenia Strategic Agreement
BRIEF

published on 01/12/2026 at 09:05, 18 days 7 hours ago

Biophytis to Engage in Major Healthcare and Investment Events

Biophytis BIOMED Forum Longevity Therapies Healthcare Investment JP Morgan Healthcare
REGULATED PRESS RELEASE

published on 01/12/2026 at 09:00, 18 days 7 hours ago

Biophytis to Participate in the JP Morgan Healthcare Conference and the Biomed Forum
Biophytis announces participation in JP Morgan Healthcare Conference and Biomed Forum in January 2026, presenting latest operational and clinical progress

Biophytis BIOMED Forum Age-related Diseases JP Morgan Healthcare Conference Transformative Therapies
PRESS RELEASE

published on 01/12/2026 at 08:59, 18 days 7 hours ago

Biophytis to Participate in the JP Morgan Healthcare Conference and the Biomed Forum
Biophytis to participate in JP Morgan Healthcare Conference and Biomed Forum to engage with global financial and pharmaceutical communities for 2026 outlook

Biophytis BIOMED Forum Healthcare Conference JP Morgan 2026
BRIEF

published on 11/13/2025 at 18:35, 2 months 16 days ago

Results of Biophytis' General Meeting Held on November 13, 2025

Financial Statements Biophytis Shareholder Approval General Meeting Thérapies
REGULATED PRESS RELEASE

published on 11/13/2025 at 18:30, 2 months 16 days ago

RESULTS OF THE COMBINED GENERAL MEETING ON NOVEMBER 13, 2025
Biophytis SA announces the approval of all resolutions at the combined general meeting held on November 13, 2025, impacting longevity therapies development. Shareholder mobilization led to a 31% quorum

Longevity Therapies Combined General Meeting Biophytis SA Shareholder Mobilization Approval Of Resolutions
BRIEF

published on 10/30/2025 at 23:05, 2 months 30 days ago

Biophytis Announces Strategic Partnerships and Financial Results for H1 2025

Financial Results Strategic Partnerships Obesity Treatment Sarcopenia Clinical Trial Biophytis Expansion
REGULATED PRESS RELEASE

published on 10/30/2025 at 23:00, 2 months 30 days ago

Biophytis Reports First-Half 2025 Results and Provides Strategic Update
Biophytis reports first-half 2025 financial results and strategic update, including milestones in sarcopenia and obesity, highlighting expansion plans and financial elements

Financial Results Biophytis Sarcopenia Strategic Update Obesity
PRESS RELEASE

published on 10/30/2025 at 22:59, 2 months 30 days ago

Biophytis Reports First-Half 2025 Results and Provides Strategic Update
Biophytis reports financial results for the first half of 2025, strategic update, and key achievements in sarcopenia and obesity. Plans for Phase 2 and Phase 3 studies outlined with focus on sustaining growth and value creation

Financial Results Biophytis Sarcopenia Strategic Update Obesity

Published on 01/30/2026 at 14:00, 2 hours 15 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 7 hours 40 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 8 hours 15 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 14 hours ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 16 hours 15 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

Published on 01/30/2026 at 16:00, 15 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Dauch Corporation
Published on 01/30/2026 at 15:59, 16 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 01/30/2026 at 15:58, 17 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Glencore plc
Published on 01/30/2026 at 15:57, 18 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/30/2026 at 15:56, 19 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc

View all EQS

Published on 01/30/2026 at 08:00, 8 hours 15 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 22 hours 15 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 22 hours 30 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 22 hours 30 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 22 hours 35 minutes ago

ALTEN: Annual revenue 2025

View all LES ECHOS COMFI WIRE

News